New data show treatment with etesevimab (JS016) and bamlanivimab together reduced risk of COVID-19 hospitalizations and death by 70 percent

Trial met primary endpoint and key secondary endpoints with high statistical significance Results from more than 1,000 high-risk patients were consistent with previous data In November, Lilly submitted a EUA request to the FDA for etesevimab and bamlanivimab together for mild to moderate COVID-19 in high-risk patients, which remains under review by the FDA Findings […]

Read More